Bacillus Calmette-Guerin Immunotherapy for Cancer

被引:35
作者
Cardillo, Fabiola [1 ]
Bonfim, Maiara [1 ]
da Silva Vasconcelos Sousa, Periela [2 ,3 ]
Mengel, Jose [2 ,4 ]
Ribeiro Castello-Branco, Luiz Roberto [5 ]
Pinho, Rosa Teixeira [2 ]
机构
[1] Fiocruz MS, Lab Mol & Struct Pathol, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil
[2] Fiocruz MS, Clin Immunol Lab, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil
[3] Fluminense Fed Univ, Lab Mol Virol & Marine Biotechnol, BR-24220008 Niteroi, RJ, Brazil
[4] UNIFASE, Fac Med Petropolis, BR-25680120 Petropolis, RJ, Brazil
[5] Ataulpho Paiva Fdn, BR-20941070 Rio De Janeiro, RJ, Brazil
关键词
BCG; cancer; trained immunity; CELL-WALL SKELETON; IMMUNE CHECKPOINT BLOCKADE; SUPERFICIAL BLADDER-CANCER; ADJUVANT IMMUNOTHERAPY; DENDRITIC CELLS; NONSPECIFIC PROTECTION; VACCINATION PROTECTS; BCG IMMUNOTHERAPY; TUMOR-REGRESSION; TRAINED IMMUNITY;
D O I
10.3390/vaccines9050439
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bacillus Calmette-Guerin (BCG), an attenuated vaccine from Mycobacterium bovis, was initially developed as an agent for vaccination against tuberculosis. BCG proved to be the first successful immunotherapy against established human bladder cancer and other neoplasms. The use of BCG has been shown to induce a long-lasting antitumor response over all other forms of treatment against intermediate, non-invasive muscle bladder cancer Several types of tumors may now be treated by releasing the immune response through the blockade of checkpoint inhibitory molecules, such as CTLA-4 and PD-1. In addition, Toll-Like Receptor (TLR) agonists and BCG are used to potentiate the immune response against tumors. Studies concerning TLR-ligands combined with BCG to treat melanoma have demonstrated efficacy in treating mice and patients This review addresses several interventions using BCG on neoplasms, such as Leukemia, Bladder Cancer, Lung Cancer, and Melanoma, describing treatments and antitumor responses promoted by this attenuated bacillus. Of essential importance, BCG is described recently to participate in an adequate microbiome, establishing an effective response during cell-target therapy when combined with anti-PD-1 antibody, which stimulates T cell responses against the melanoma. Finally, trained immunity is discussed, and reprogramming events to shape innate immune responses are addressed.
引用
收藏
页数:15
相关论文
共 136 条
  • [41] Guilty as charged: B-RAF is a human oncogene
    Garnett, MJ
    Marais, R
    [J]. CANCER CELL, 2004, 6 (04) : 313 - 319
  • [42] Immunodietica: interrogating the role of diet in autoimmune disease
    Gershteyn, Iosif M.
    Burov, Andrey A.
    Miao, Brenda Y.
    Morais, Vasco H.
    Ferreira, Leonardo M. R.
    [J]. INTERNATIONAL IMMUNOLOGY, 2020, 32 (12) : 771 - 783
  • [43] Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly
    Giamarellos-Bourboulis, Evangelos J.
    Tsilika, Maria
    Moorlag, Simone
    Antonakos, Nikolaos
    Kotsaki, Antigone
    Dominguez-Andres, Jorge
    Kyriazopoulou, Evdoxia
    Gkavogianni, Theologia
    Adami, Maria-Evangelia
    Damoraki, Georgia
    Koufargyris, Panagiotis
    Karageorgos, Athanassios
    Bolanou, Amalia
    Koenen, Hans
    van Crevel, Reinout
    Droggiti, Dionyssia-Irene
    Renieris, George
    Papadopoulos, Antonios
    Netea, Mihai G.
    [J]. CELL, 2020, 183 (02) : 315 - +
  • [44] Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy
    Gil-Cruz, Cristina
    Perez-Shibayama, Christian
    De Martin, Angelina
    Ronchi, Francesca
    van der Borght, Katrien
    Niederer, Rebekka
    Onder, Lucas
    Lutge, Mechthild
    Novkovic, Mario
    Nindl, Veronika
    Ramos, Gustavo
    Arnoldini, Markus
    Slack, Emma M. C.
    Boivin-Jahns, Valerie
    Jahns, Roland
    Wyss, Madeleine
    Mooser, Catherine
    Lambrecht, Bart N.
    Maeder, Micha T.
    Rickli, Hans
    Flatz, Lukas
    Eriksson, Urs
    Geuking, Markus B.
    Mccoy, Kathy D.
    Ludewig, Burkhard
    [J]. SCIENCE, 2019, 366 (6467) : 881 - +
  • [45] Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
    Gopalakrishnan, V.
    Spencer, C. N.
    Nezi, L.
    Reuben, A.
    Andrews, M. C.
    Karpinets, T. V.
    Prieto, P. A.
    Vicente, D.
    Hoffman, K.
    Wei, S. C.
    Cogdill, A. P.
    Zhao, L.
    Hudgens, C. W.
    Hutchinson, D. S.
    Manzo, T.
    de Macedo, M. Petaccia
    Cotechini, T.
    Kumar, T.
    Chen, W. S.
    Reddy, S. M.
    Sloane, R. Szczepaniak
    Galloway-Pena, J.
    Jiang, H.
    Chen, P. L.
    Shpall, E. J.
    Rezvani, K.
    Alousi, A. M.
    Chemaly, R. F.
    Shelburne, S.
    Vence, L. M.
    Okhuysen, P. C.
    Jensen, V. B.
    Swennes, A. G.
    McAllister, F.
    Sanchez, E. Marcelo Riquelme
    Zhang, Y.
    Le Chatelier, E.
    Zitvogel, L.
    Pons, N.
    Austin-Breneman, J. L.
    Haydu, L. E.
    Burton, E. M.
    Gardner, J. M.
    Sirmans, E.
    Hu, J.
    Lazar, A. J.
    Tsujikawa, T.
    Diab, A.
    Tawbi, H.
    Glitza, I. C.
    [J]. SCIENCE, 2018, 359 (6371) : 97 - 103
  • [46] Vaccination strategies to reduce the risk of leukaemia and melanoma
    Grange, JM
    Stanford, JL
    Stanford, CA
    Kömel, KF
    [J]. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (08) : 389 - 392
  • [47] Infection, immune responses and the aetiology of childhood leukaemia
    Greaves, M
    [J]. NATURE REVIEWS CANCER, 2006, 6 (03) : 193 - 203
  • [48] Immunity, Inflammation, and Cancer
    Grivennikov, Sergei I.
    Greten, Florian R.
    Karin, Michael
    [J]. CELL, 2010, 140 (06) : 883 - 899
  • [49] Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer
    Hecht, SS
    [J]. CARCINOGENESIS, 2002, 23 (06) : 907 - 922
  • [50] BCG AS ADJUVANT IMMUNOTHERAPY FOR NEOPLASIA
    HERSH, EM
    GUTTERMAN, JU
    MAVLIGIT, GM
    [J]. ANNUAL REVIEW OF MEDICINE, 1977, 28 : 489 - 515